Intraperitoneal inflammation decreases endometriosis in a mouse model

Nowak, Nicola M.; Fischer, Oliver M.; Gust, Tatjana C; Fuhrmann, Ulrike; Habenicht, U.‐F.; Schmidt, Anja

doi:10.1093/humrep/den189

Cited by 27 publications

(14 citation statements)

References 43 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endometriosis was induced according to a method reported by Nowak et al [18], with slight modifications [18]. A schematic diagram representing the induction and confirmation of endometriosis in mice is shown in Figure 2.…”

Section: Endometriosis Induction and Confirmationmentioning

confidence: 99%

Letrozole and Curcumin Loaded-PLGA Nanoparticles: A Therapeutic Strategy for Endometriosis

Jana¹

2014

J Nanomedine Biotherapeutic Discov

View full text Add to dashboard Cite

Clinical treatment of endometriosis, a common gynaecological disorder, still remains a challenge. Hormonal suppression, pain relief medication and surgical intervention are the conventional treatment modalities; however, frequent recurrence of the disease renders the results unsatisfactory. Given the fact that oxidative stress, angiogenesis, excessive matrix degradation, and aromatase activity are associated with endometriosis, we were motivated to use the combinatorial effect of two drugs, Curcumin (Cur) and Letrozole (Let) encapsulated in PLGA and test their efficacy in mice induced with the disease. The nanoparticles (NPs) were synthesized using solvent evaporation method and characterization indicated the spherical particles to be monodispersed, polymorphic, small in size with high encapsulation efficiency, without having a tendency for significant aggregation or adhesion. Following standardization, 40mg/kg body weight of NPs was administered in endometriotic mice. Oxidative stress parameters, angiogenic markers, matrix degrading molecules, estrogen levels and endometriotic lesions, were assessed and compared before and after administration. Let-Cur NPs treatment in vivo, in addition to decreasing these parameters significantly, was also successful in reducing endometrial glands and micro-vessels density in the peritoneum to a considerable extent, thereby indicating significant regression of the disease. This is a proof of concept study. Pre-clinical non-human primate studies for testing the safety and efficacy of these NPs at larger doses in endometriosis is suggested. Citation: Jana SK, Chakravarty B, Chaudhury K (2014) Letrozole and Curcumin Loaded-PLGA Nanoparticles: A Therapeutic Strategy for Endometriosis.

show abstract

Section: Endometriosis Induction and Confirmationmentioning

confidence: 99%

Letrozole and Curcumin Loaded-PLGA Nanoparticles: A Therapeutic Strategy for Endometriosis

Jana¹

2014

J Nanomedine Biotherapeutic Discov

View full text Add to dashboard Cite

show abstract

“…Of chemical etiological factors, one should note bases [116] and reducing substances [118,119]. Effects of acids are at best controversial, having in mind their procoagulative and therefore burn-like activity.…”

Section: Causes Of Inflammationmentioning

confidence: 99%

Definition of Inflammation, Causes of Inflammation and Possible Anti-inflammatory Strategies

Stankov¹

2012

TOINFJ

View full text Add to dashboard Cite

Current definition of inflammation by its cardinal signs is obsolete and unsuitable for guiding adequate therapeutic strategies. Furthermore, present theory of the inflammatory process regarding vascular phenomena as essential for generation of cardinal signs is invalid and unable to explain well established empirical facts, particularly the extent of the osmotic pressure and temperature variations within the inflamed tissue.

show abstract

“…Endometriosis was experimentally induced using a modification of the EGFP mouse model reported by nowak et al (21). our model consisted of female c57BL/6-tg(ActB-EGFP)1osb/J mice which ubiquitously express green fluorescent protein (EGFP; Jackson Laboratories, Bar Harbor, ME) which were used as recipients and immature c57BL/6 wild-type female mice (Jackson Labs) which served as uterine tissue donors.…”

Section: Mouse Model Of Endometriosismentioning

confidence: 99%

Inhibition of Macrophage Migration Inhibitory Factor Reduces Endometriotic Implant Size in Mice with Experimentally Induced Disease

Nothnick

Colvin

Cheng

et al. 2011

Journal of Endometriosis

View full text Add to dashboard Cite

Aim Macrophage migration inhibitory factor (MIF) is a cytokine whose expression is elevated in endometriotic tissue from women with the disease but the functional role of this factor in the pathogenesis of the disease is uncertain. The objective of the current study was to examine the role of MIF in the pathogenesis of endometriosis. Method Experimental endometriosis was induced in mice and the ability of the MIF antagonist, ISO-1, to reduce endometriotic implant size was assessed. Results Administration of ISO-1 resulted in a significant reduction in implant size and vascularity (as assessed by Flk1 mRNA expression) which was not associated with an alteration in the reproductive cycle. Conclusion These data suggest that inhibition of MIF activity is associated with a significant reduction in endometriotic implant size and leads us to speculate that a similar approach of targeting MIF may prove useful in treating endometriosis in humans.

show abstract

Intraperitoneal inflammation decreases endometriosis in a mouse model

Cited by 27 publications

References 43 publications

Letrozole and Curcumin Loaded-PLGA Nanoparticles: A Therapeutic Strategy for Endometriosis

Letrozole and Curcumin Loaded-PLGA Nanoparticles: A Therapeutic Strategy for Endometriosis

Definition of Inflammation, Causes of Inflammation and Possible Anti-inflammatory Strategies

Inhibition of Macrophage Migration Inhibitory Factor Reduces Endometriotic Implant Size in Mice with Experimentally Induced Disease

Contact Info

Product

Resources

About